Cancer Research UK scientists have developed a system for treating hard-to-reach tumours, using nanoparticles to guide a ‘tumour busting’ gene to cancer cells. The results of this study are published today (Thursday) in the journal Cancer Research*.
Scientists from Cancer Research UK’s Centre for Oncology and Applied Pharmacology at the University of Glasgow, carried out laboratory tests on tumours of the cervix, bowel and other cells that line the body. Within 24 hours of treatment, the tumours began to shrink, resulting in prolonged survival in all, and even cures in some cases.
The promising results of these experiments could make it possible to treat inaccessible tumours in humans using gene therapy in the future.
This new treatment can selectively target cancer cells, without causing damage to surrounding healthy cells. Standard cancer treatment, such as chemotherapy, indiscriminately attacks all the cells in the region, which can lead to unpleasant side effects for patients.
Some tumours are inoperable, for example, if they are close to vital organs such as the heart or lungs. Tumours that cannot be removed by surgery are commonly associated with a poor prognosis and survival.
In order to kill cancer cells at difficult tumour sites, gene medicines have to make an arduous journey through the body’s blood vessels, where they have to travel across the vessel wall into the tumour and finally into the cancerous cell. In this treatment, nanoparticles containing a combination of specially designed tiny molecules are used to transport a gene called TNF alpha to the affected cells.
The TNF alpha gene has a built-in switch that enables it to only become activated in cells that are cancerous. TNF has highly toxic properties that cause cells to die, which is why it is crucial that it is only activated in cancer cells.
Dr Andreas Schätzlein, lead researcher of the study, says: “Our research focussed on finding the right compounds to make the prospect of nanoparticle gene therapy a realistic treatment option. We found that the combination of an effective delivery system, along with the gene’s clever ability to target cancer cells, is key to the success of this treatment.
”This is the first time that this type of treatment has been able to reduce the size of tumours to such an extent, so we hope to have further demonstrated the potential of genetic therapies to treat cancer in the future. Our efforts will now focus on understanding whether such systems can be used as a platform to deliver other genes and how to best harness the potential benefits to safely treat a broader range of tumours in the clinic.”
Professor Jim Cassidy, Cancer Research UK’s Director of Medical Oncology based at the University of Glasgow, says: “Gene therapy is a promising therapeutic approach that has been hampered by a lack of efficient and safe means of delivery. The fact that these experiments effectively destroyed the tumours in a lab setting is extremely encouraging news.
”Cancer Research UK is committed to finding new ways of treating cancer, and I am delighted that here in Scotland we have made such an important step in developing a type of therapy that could have benefits for cancer patients in years to come.”
For media enquiries please contact Steve Palmer on 020 7061 8312 or, out-of-hours, the duty press officer on 07050 264 059.
- Synthetic Anticancer Gene Medicine Exploits Intrinsic Antitumor Activity of Cationic Vector to Cure Established Tumours. Cancer Research. Christine Dufès, W Nicol Keith, Alan Bilsland, Irina Proutski, Ijeoma F Uchegbu and Andreas G Schatzlein.
- The research was supported by University of Glasgow, The University of Strathclyde, Scottish Enterprise and the Biotechnology and Biological Sciences Research Council (BBSRC).
Cancer Research UK
- Cancer Research UK’s vision is to conquer cancer through world-class research.
- The charity works alone and in partnership with others to carry out research into the biology and causes of cancer, to develop effective treatments, improve the quality of life for cancer patients, reduce the number of people getting cancer and to provide authoritative information on cancer. Cancer Research UK is the world’s leading independent charity dedicated to research on the causes, treatment and prevention of cancer.
- For further information about Cancer Research UK’s work or to find out how to support the charity, please call 020 7121 6699 or visit the Cancer Research UK website.
The Biotechnology and Biological Sciences Research Council (BBSRC) is the UK funding agency for research in the life sciences. Sponsored by Government, BBSRC annually invests around £336 million in a wide range of research that makes a significant contribution to the quality of life for UK citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, healthcare and pharmaceutical sectors.